Last reviewed · How we verify
LY573636-sodium
LY573636-sodium is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 2 development. Also known as: Tasisulam, LY573636, Tasisulam-sodium, tasisulam.
LY573636-sodium is a small molecule used in clinical trials for various cancer types, including sarcoma, melanoma, non-small-cell lung cancer, and acute myeloid leukemia. It has been studied in combination with other treatments, such as paclitaxel, in trials for metastatic soft tissue sarcoma and other advanced solid tumors.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LY573636-sodium |
|---|---|
| Also known as | Tasisulam, LY573636, Tasisulam-sodium, tasisulam |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma (PHASE2)
- A Phase 1 Study in Patients With Solid Tumors (PHASE1)
- A Safety Study in Participants With Advanced Solid Tumors (PHASE1)
- Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia (PHASE1)
- A Phase 1b Trial in Patients With Renal Cell Cancer (PHASE1)
- Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors (PHASE1)
- Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer (PHASE2)
- A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY573636-sodium CI brief — competitive landscape report
- LY573636-sodium updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about LY573636-sodium
What is LY573636-sodium?
Who makes LY573636-sodium?
Is LY573636-sodium also known as anything else?
What development phase is LY573636-sodium in?
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Also known as: Tasisulam, LY573636, Tasisulam-sodium, tasisulam
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing